Injectable microsphere applications for cattle and companion animals begin with the poly(lactide-co-glycolide) veterinary grade API supplied as a lyophilized powder for tablets, injections, capsules, powders, granules, premix, and solutions. A 50:50 lactide-to-glycolide copolymer with acid-terminated end groups is lyophilized to a water content below 0.5 wt% and then aseptically micronized to a particle size d50 between 15 μm and 45 μm. The micronized powder is dispersed into an ice-cooled aqueous polyvinyl alcohol solution at 2 °C to 8 °C using a rotor-stator homogenizer with tip speed maintained above 12 m/s; the resulting oil-in-water emulsion is transferred to a 100 L jacketed glass reactor where dichloromethane evaporation is controlled by nitrogen sweep at a rate of 0.6 L/min per kg of emulsion. Batch records from production-scale lines show residual dichloromethane between 180 ppm and 420 ppm when inlet gas flow drops below the set point for more than 15 min, while continuous flow keeps the residual solvent below 150 ppm. Release testing in phosphate-buffered saline at 37 °C and pH 7.4 demonstrates an initial lag of 6 h to 72 h followed by erosion-controlled release from day 18 to day 42; the initial burst is measured by the cumulative fraction released at 4 h and must remain below 10% for injectable use in cattle. Subcutaneous administration through a 21 G needle at a dose of 12 mg/kg body weight requires a d90 below 95 μm, because particles above 80 μm cause needle clogging in more than 5% of injections during field handling. Subvisible particulate matter is tested by the light obscuration method of USP <787>, and the finished injectable must meet USP <71> sterility requirements. Terminal gamma irradiation at 25 kGy is possible only for low-loading batches because irradiation above 15 kGy reduces inherent viscosity by approximately 0.05 dL/g and shifts burst release from 8% to 19% at 4 h; aseptic processing is therefore used when residual glycolide monomer exceeds 0.05 wt%. Residual solvent compliance follows ICH Q3C options for Class 2 solvents.

The values above represent typical ranges observed under sink conditions; published data for exact subcutaneous bovine tissue degradation remain limited.

What Limits Direct Compression of a PLGA Veterinary Tablet for Companion Animals?

On rotary tablet presses used for companion animal dosing, direct compression of a PLGA veterinary tablet is governed primarily by the glass transition temperature of the selected copolymer grade, which ranges from 45 °C to 55 °C for 75:25 and 85:15 lactide-to-glycolide ratios. The API is blended with anhydrous dicalcium phosphate, crospovidone, and magnesium stearate in a V-blender at 25 rpm for 15 min; lubricant addition is limited to 0.5 wt% because magnesium stearate above 1.0 wt% reduces tablet breaking force by more than 20% at a compression force of 20 kN. An eight-station rotary press with 8 mm flat-face punches is operated at a target hardness of 7 kP to 12 kP; tablet breaking force is evaluated by USP <1217>, and friability is tested per USP <1216>. Aqueous film coating creates a process conflict because PLGA undergoes surface hydrolysis within 20 min when exposed to inlet air at 60 °C and spray moisture above 1.5 g/min; the tablet must therefore receive an ethylcellulose seal coat in ethanol before any aqueous enteric layer is applied. Dissolution testing with USP <711> Apparatus II at 50 rpm and 900 mL buffer at pH 6.8 containing 0.5% sodium dodecyl sulfate yields drug release below 10% at 2 h for sustained-release matrices and between 55% and 80% at 12 h, depending on PLGA content from 20 wt% to 40 wt%. Residual moisture in the bulk API before dry blending should be below 0.3 wt%; otherwise the powder sticks to tooling during long compression runs and tablet weight variation exceeds ±3%. Score-line accuracy for divided dosing is validated by USP <905> uniformity of dosage units. Amine-containing fillers must be avoided because primary and secondary amines catalyze ester hydrolysis and reduce matrix integrity during stability storage at 40 °C and 75% relative humidity for 6 months.

Swine and poultry feed mills process the PLGA veterinary API as a microencapsulated dry powder rather than as uncoated polymer, because direct API particles segregate during pneumatic conveying and produce assay variability above 10%. The powder is spray-dried with a hydrophobic coating onto a sucrose-starch carrier to a mean granule size between 150 μm and 850 μm, then transferred to a ribbon blender filled to 60% of capacity. Mixing with ground corn at 10 rpm for 10 min achieves a coefficient of variation below 5% when sampled by ISO 6497 procedures and assayed by a validated high-performance liquid chromatography method. Moisture content in the finished feed must remain below 14% to prevent premature PLGA hydrolytic degradation; at moisture above 16%, the ester backbone loses mass integrity within 28 days at 25 °C. Granulation in a fluidized bed with a top-spray insert requires inlet air at 55 °C to 65 °C and product temperature below 38 °C; binder solution addition above 25 g/min causes agglomerate caking on the distributor plate and reduces yield below 70%. Medicated feed production falls under 21 CFR Part 225 current good manufacturing practice, and batch records must document drug carryover below 5% of the labeled active concentration. The premix is often diluted at the farm before administration; field mixing studies show that manual scoop addition into a vertical feed mixer yields unacceptable assay non-uniformity unless a pre-blend step with 2 kg dry carrier per 1 kg premix is performed for 5 min. Swine, poultry, and companion animal feed intakes differ, so the active concentration in the final ration is adjusted by body weight and metabolic clearance rather than by a single premix strength. Granules filled into water-soluble sachets for oral suspension must disintegrate within 3 min when reconstituted in water at 25 °C; otherwise drug release in the drinking water system is incomplete and the static mixer line clogs.

When a Sterile PLGA Solution Must Form an In Situ Depot After Subcutaneous Injection

Because a sterile injectable solution must gel in situ after subcutaneous injection, a 75:25 acid-terminated PLGA is dissolved in N-methyl-2-pyrrolidone at a polymer concentration from 10 wt% to 30 wt%; the solution dynamic viscosity measured by cone-plate viscometry at 25 °C ranges from 300 mPa·s to 800 mPa·s, and above that range terminal filtration through a 0.22 μm membrane becomes impractical. The API and polymer solution are filled into siliconized glass vials under dry nitrogen, and residual water in the solvent is held below 0.05 wt% because water accelerates polymer chain scission before injection. Upon injection into subcutaneous tissue, the water-miscible solvent exchanges with body fluid and leaves a semi-solid depot; the lag time to coherent precipitate is measured in an agarose gel model at 37 °C, where a 20 wt% PLGA formulation forms a stable gel within 8 min to 15 min. Release from a 20 wt% depot in swine has a duration of 21 days to 42 days when the lactide:glycolide ratio is 75:25; changing to 50:50 shortens the erosion phase to 14 days to 28 days but increases initial solvent-related burst. Injection force through an 18 G needle at a rate of 0.5 mL/min should be below 25 N; higher force leads to vacuum bubble entrapment and variable delivery volume. Because N-methyl-2-pyrrolidone is a Class 2 residual solvent, the target daily exposure is aligned with ICH Q3C permitted daily exposure, and tissue reaction studies follow ISO 10993-6:2016 intramuscular implantation testing. Batch-to-batch viscosity shifts above ±10% on a 5 kg mixing vessel occur when the PLGA has residual monomer above 0.08 wt% or when dissolution temperature exceeds 60 °C; such batches show syringeability failures in automated filling lines with 10 mL cartridge fill volumes.

Oro-Dispersible Capsule Multiparticulates for Canine Gastric Resistance

For dogs requiring long-term oral therapy, capsule multiparticulates are manufactured by coating PLGA microparticles with an acid-resistant polymethacrylate film, then filling hard gelatin capsules at a target fill weight of 250 mg to 350 mg. The microparticle core is produced by emulsion-solvent evaporation using a 65:35 PLGA with an inherent viscosity of 0.35 dL/g to 0.48 dL/g; the core d50 is controlled to 180 μm to 425 μm for rapid flow through a capsule filling machine. Fluidized-bed coating is carried out in a Wurster column with inlet air at 35 °C to 40 °C, product temperature at 26 °C to 28 °C, and spray rate from 8 g/min to 12 g/min; coating thickness is expressed as weight gain from 20% to 35%. Drug release is tested with USP <711> Apparatus I at 100 rpm; the acid stage of 0.1 N hydrochloric acid for 2 h must release not more than 10%, and the subsequent buffer stage at pH 6.8 must release at least 80% within 45 min. Capsule filling requires the microparticle bulk density to remain between 0.35 g/mL and 0.55 g/mL; outside that range, fill weight variability exceeds ±5% and some capsules fall outside USP <905> uniformity limits. Storage of filled capsules at relative humidity above 60% reduces shell brittleness but increases PLGA hydrolysis at the microparticle surface; desiccant is inserted when the product is packaged in multi-dose bottles. Residual primary amines in the capsule shell or banding solution must be avoided because they accelerate PLGA chain scission and shift the 12 h dissolution point upward by more than 15%. Production-scale behavior shows that operator-dependent feeding of the Wurster column can produce agglomerated slugs at the bottom screen when inlet air distributor pressure is below 0.8 bar.

Poultry oral solution and suspension manufacturing starts with wet milling of the PLGA veterinary API in an aqueous vehicle containing a polymeric stabilizer to a final d90 below 20 μm. The milled suspension is thickened with xanthan gum at 0.3 wt% to 0.6 wt% to a viscosity of 150 mPa·s to 350 mPa·s at 25 °C; this range prevents settling during storage at 2 °C to 8 °C for 72 h while still passing through drinking water metering pumps at 1 L/min. Zeta potential measured by electrophoretic light scattering remains below -30 mV for stable batches, while values between -15 mV and -25 mV predict caking within 30 days. The microencapsulated PLGA particles protect the API from hydrolysis in chlorinated drinking water at free chlorine levels up to 3 ppm, but above that level the polymer surface oxidizes and release kinetics shift from first-order to biphasic. In a header tank administration system for broilers, calculated daily water intake is 1.6 L/kg to 2.0 L/kg body weight, and the active concentration in the final drinking solution is adjusted by a metering pump dilution setting of 1:100 to 1:200. The reconstituted suspension is used within 24 h after mixing; beyond that window, bacterial growth and polymer sedimentation create dose non-uniformity above 10%. Stability studies at 25 °C and 60% relative humidity for 24 months require the dry powder to retain an assay of 95% to 105% and a moisture content below 1.0 wt%; batches stored in aluminum foil pouches with desiccant meet this, while low-density polyethylene bags exceed water content limits within 6 months. Plastic packaging contact is evaluated by USP <661.1> suitability testing.